Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (682)	5/5/1998 10:17:00 AM
From: Merav	Read Replies (4) \| Respond to of 1491

Pharmos cancer drug is as good as Entremed's, I'm surprised nobody has picked up on this, especially since Entremed was the talk of Wall Street yesterday. When I say as good as Entremed I mean that Pharmos' Tamoxifen derivative has also been shown to destroy cancer tumors in mice by choking the blood supply. This is what Entremed's big story in the New York Times was all about. But if you look at a story from the Science section of Ha'aretz, the influential Israeli daily from January 29, 1997 you will see a feature on Pharmos headlined "The Tumour Was Choked To Death--a molecule discovered by an Israeli researcher stops cancerous growths by blocking blood vessels ". The story describes how in a spinoff discovery during an experiment comparing the Pharmos anti-cancer drug with Tamoxifen, Pharmos showed that its drug was much more effective in eliminating tumors altogether than Tamoxifen was. The study showed that the Pharmos drug caused tumors in mice to be completely eliminated within 6 weeks in 40 percent of all mice tested. (Tamoxifen stops growth from spreading but does not destroy existing tumors). The researchers concluded that the Pharmos drug's mechanism of activity related to its ability to stop tumors from getting a supply of blood. I would expect the surge in interest in drugs that fight cancer by choking the blood supply to tumors should benefit Pharmos. Neither Entremed or Pharmos has yet to try their drugs on humans.